PC at work
Peter Cresswell has two great posts at the moment.
The first is about how the Hutt City Mayor blamed the Kelson landslip on climate change (which has become the univeral cause of all problems it seems). However a geologist has found it may have been a leaking council sewer pipe!!
The second is about letters to the NZ Herald on Labour’s refusal to pay back the $446,000 cost of its pledge cards. Of all the letters on the topic, only one was defending the Government. Who was this noble citizen? None other than the husband of Helen Clark’s electorate agent!
I wonder if Helen wrote the letter herself!!
No TweetBacks yet. (Be the first to Tweet this post)
Tags: Blogosphere
August 11th, 2006 at 1:49 pm
Well that would make a nice change. She writes something and someone ELSE signs it.
August 11th, 2006 at 1:53 pm
Nice one Murray
August 11th, 2006 at 3:53 pm
Burned evidence in a fraud case… Wouldn’t happen in NZ – people would go to jail for that !
August 11th, 2006 at 5:39 pm
I didn’t know Lair bore fans could read and now your are telling me they can write, will wonders ever cease.
August 11th, 2006 at 7:10 pm
Nice one Side Show
Loved the term “liar bore”
August 11th, 2006 at 8:04 pm
Sub-cretinous “useful idiots” running about jerking your flabby limbs around in pointless tiresome little circles bleating “corruption”…ha. It is all a smokescreen for the real corruption. Bash’s connivance with the EB’s and others has been covered up with nothing but noise and distraction ever since the election, while twatville here is obessesed with mindless drek.
You patsy boys remind me of nothing less than all those brain-dead right wingers who screeched endlessly about Clinton’s fricken blow-job in the 90′s…and who are now trapped into helplessly backing a Bush administration whose lies, treachery and flatout perversion of sanity has reduced the entire American political circus to a sick joke. If ever a National govt ever manages to buy it’s way to wrapping it’s slimy tentacles back around the levers of power, we will look back on these days as some kind of quaint innocent prelude to a nightmare.
Get off the net you greasy tossers and go and do something useful this weekend.
August 11th, 2006 at 8:10 pm
get a life, vlad
August 11th, 2006 at 8:36 pm
Enjoy your weekend release!
August 11th, 2006 at 11:18 pm
Vlad shows such great logic he should be a professor.
The Brethren spending their own money is corrupt while Labour spending taxpayer money on a pledge card and refusing the Auditor-Generals’s request to pay it back is not corrupt!!
August 12th, 2006 at 12:36 am
EB excluded to identify required details with some of their campaign releases – like in not supplying valid info about those authorising the advertising. That is a known breach of practice.
I think the premise of which should extend to all political spending – the sources should be identified. Every donation to a political party – from membership fees to contributions should be info made available to the public.
As to the Auditor General’s decision – on what post 2002 basis was it made. If it is an assessment of earlier requirements, why is this report the first to take this position?
August 12th, 2006 at 8:47 am
Labour not paying back this money is telling me that they don’t intend/hope to get into government in 2008.
DPF, just make sure that Murray, or Bill, or John or whoever is leader of the National Party at that time reminds us of this sour episode in NZ political history.
November 23rd, 2006 at 3:57 am
The heart that once truly loves never forgets… Hector
November 23rd, 2006 at 3:57 am
The heart that once truly loves never forgets… Hector
November 23rd, 2006 at 3:58 am
The heart that once truly loves never forgets… Hector
April 2nd, 2007 at 12:50 pm
Excellent resource you’ve got here! http://tramadol-side-effects1.blogspot.com/
April 3rd, 2007 at 5:58 am
Wonderful articles. Thanks for such a nice information http://tlurl.com/?vIyMKgfC
April 8th, 2007 at 3:06 pm
ioflx qvxgediz tnzoi tycvlaigm tahmyrfow ehzwmtf omnauislv
April 16th, 2007 at 4:47 pm
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
April 18th, 2007 at 3:25 am
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
April 19th, 2007 at 12:15 pm
Useful information. Good job. http://houseboiler.jubiiblog.co.uk
April 20th, 2007 at 9:26 am
What a great site and excellent resource you have. http://yachtcruises.iphorum.com/
May 5th, 2007 at 10:24 pm
Really amazing! Keep working. http://jackets.blogtopia.com/
May 6th, 2007 at 11:41 pm
This site rocks! Keep up that excellent work! http://jewelleryboxes.vdforum.ru
May 8th, 2007 at 2:50 pm
Wonderful articles. Thanks for such a nice information http://engagementring.blogtopia.com/
May 9th, 2007 at 10:28 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 10th, 2007 at 12:15 am
Hello, your site is superb http://jewellery.aceblog.fr/
May 10th, 2007 at 8:22 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 10th, 2007 at 6:09 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 11th, 2007 at 12:36 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 11th, 2007 at 3:43 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 12th, 2007 at 7:56 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 12th, 2007 at 1:00 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 12th, 2007 at 5:55 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 12th, 2007 at 11:11 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 13th, 2007 at 9:33 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 13th, 2007 at 2:38 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 14th, 2007 at 1:44 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 18th, 2007 at 1:41 am
Really amazing! Keep working.
http://ultrasound.vdforum.ru
May 23rd, 2007 at 10:17 am
Thank you for a very informative site. http://diets.spotbb.com/
May 25th, 2007 at 10:08 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 25th, 2007 at 4:19 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 26th, 2007 at 1:35 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 26th, 2007 at 6:06 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 26th, 2007 at 10:50 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 26th, 2007 at 10:10 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 27th, 2007 at 3:11 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 27th, 2007 at 8:47 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 27th, 2007 at 2:05 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 28th, 2007 at 12:16 am
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 28th, 2007 at 3:59 pm
On Friday, the first day after Merck’s loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor’s. In addition, Dr. Reddy’s Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA’s decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis’ generic drug unit, to delay the agency’s approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public’s access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week — versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal — could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
June 1st, 2007 at 4:56 pm
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 1st, 2007 at 10:07 pm
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 3rd, 2007 at 3:54 am
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 3rd, 2007 at 8:51 am
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 3rd, 2007 at 12:50 pm
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 3rd, 2007 at 4:55 pm
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 3rd, 2007 at 9:01 pm
Really amazing! Keep working. http://plasticmodel.forumlivre.com/
June 5th, 2007 at 2:04 am
Useful information. Good job. http://tracfoneringtone.vdforum.ru/
June 6th, 2007 at 7:23 pm
Nice resource, very interesting reading. http://gifts123.iquebec.com
June 8th, 2007 at 7:41 am
The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.
The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.
“It’s not universally known that finasteride lowers PSA levels in younger men who take it for hair growth,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D’Amico of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston. “It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men.”
Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.
In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day.
“The impact of finasteride on PSA levels is significant,” said Dr. Roehrborn. “This needs to be realized by all internists, family-care doctors, dermatologists – anybody who writes prescriptions for male-pattern hair loss.”
Researchers have known for years that the same testosterone metabolism responsible for prostate growth also causes male-pattern baldness (called androgenic alopecia), Dr. Roehrborn said. Both BPH and male-pattern hair loss have to do with the male hormone testosterone, which is being converted to dihydrotestosterone (DHT) by an enzyme named 5-alpha reductase. DHT activates the genes responsible for the development of male-pattern hair loss. Finasteride interferes with this process by blocking 5-alpha reductase and preventing the conversion of testosterone to DHT.
The data in The Lancet study were collected by Dr. Roehrborn from 1998 to 2000 in cooperation with medical centers in Arizona, Colorado, Connecticut, Georgia, Indiana, Louisiana, Minnesota, New York, North Carolina, Oregon, Texas and Virginia.
The data in The Lancet study are derived from a study Dr. Roehrborn conducted with Merck & Co., Inc. in 2000. Dr. Roehrborn, discussing the reasons to publish this report now, said: “The data are published now out of recognition that there was an acknowledged gap in the primary-care community about the impact of Propecia on PSA levels. When doctors ask for their patients’ medical history, they need to ask if they have taken any drugs for hair loss, and the doctors need to multiply the PSA readings by two.”
The current study also was funded by Merck & Co., Inc.
About UT Southwestern Medical Center
UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.
UT Southwestern Medical Center
United States
cheap propecia usa
June 10th, 2007 at 9:12 am
http://miniurl.pl/buy-prozac
June 17th, 2007 at 6:00 am
Usefull information and all is good arranged. http://girlsbeddings.vdforum.ru/
June 20th, 2007 at 2:59 am
Thank you for a very informative site. http://firewood.fr33webhost.com
July 5th, 2007 at 9:05 am
I feel like a fog, not that it matters. I’ve pretty much been doing nothing , but eh. Today was a loss. I haven’t gotten much done for a while.
http://hoodia.allpillsdiscount.info/index.php?qq=hoodia gp57 hoodia gp57
See you